Johns Hopkins, the Maryland Stem Cell Research Fund and BioCardia (NSDQ:BCDA) said today that the 1st patient has been treated in a pivotal Phase III trial of the CardiAmp cell-based therapy for the treatment of ischemic heart failure.
The investigational therapy was designed to deliver a dose of a patient’s own bone marrow cells directly to the area of cardiac dysfunction after a heart attack, according to BioCardia.
Get the full story at our sister site, Drug Delivery Business News.
The post BioCardia, Johns Hopkins treats first patient with CardiAmp cell therapy in Phase III trial appeared first on MassDevice.
from MassDevice http://ift.tt/2lvSxsb
Cap comentari:
Publica un comentari a l'entrada